Tyra Biosciences公司,在2026年8月4日当天,对既有的销售协议进行了修订。此举旨在将普通股的最高发行价格予以提升。该重要信息,已通过向美国证券交易委员会(SEC)提交的文件,正式对外公布。
Tyra Biosciences公司,在2026年8月4日当天,对既有的销售协议进行了修订。此举旨在将普通股的最高发行价格予以提升。该重要信息,已通过向美国证券交易委员会(SEC)提交的文件,正式对外公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.